[go: up one dir, main page]

MX2020009604A - Composiciones y metodos para tratar el estre?imiento grave. - Google Patents

Composiciones y metodos para tratar el estre?imiento grave.

Info

Publication number
MX2020009604A
MX2020009604A MX2020009604A MX2020009604A MX2020009604A MX 2020009604 A MX2020009604 A MX 2020009604A MX 2020009604 A MX2020009604 A MX 2020009604A MX 2020009604 A MX2020009604 A MX 2020009604A MX 2020009604 A MX2020009604 A MX 2020009604A
Authority
MX
Mexico
Prior art keywords
compositions
methods
treating severe
severe constipation
dgat1
Prior art date
Application number
MX2020009604A
Other languages
English (en)
Inventor
Michael H Serrano-Wu
Brian K Hubbard
Original Assignee
Anji Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anji Pharmaceuticals Inc filed Critical Anji Pharmaceuticals Inc
Publication of MX2020009604A publication Critical patent/MX2020009604A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente descripción proporciona métodos relacionados con el tratamiento o la prevención de la disfunción gastrointestinal en un sujeto que lo necesita, que incluyen el uso de un inhibidor de la diacilglicerol O-aciltransferasa 1 (DGAT1). La descripción también proporciona composiciones farmacéuticas que comprenden un inhibidor de DGAT1, o sales o ésteres farmacéuticamente aceptables de este, útiles para los tratamientos descritos en la presente.
MX2020009604A 2018-03-16 2019-03-15 Composiciones y metodos para tratar el estre?imiento grave. MX2020009604A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862644033P 2018-03-16 2018-03-16
PCT/US2019/022499 WO2019178492A1 (en) 2018-03-16 2019-03-15 Compositions and methods for treating severe constipation

Publications (1)

Publication Number Publication Date
MX2020009604A true MX2020009604A (es) 2023-01-25

Family

ID=67904819

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009604A MX2020009604A (es) 2018-03-16 2019-03-15 Composiciones y metodos para tratar el estre?imiento grave.

Country Status (17)

Country Link
US (4) US11224590B2 (es)
EP (1) EP3765012A4 (es)
JP (1) JP7527984B2 (es)
KR (1) KR102747096B1 (es)
CN (1) CN111936137B (es)
AU (1) AU2019234956B2 (es)
BR (1) BR112020018790A2 (es)
CA (1) CA3093970A1 (es)
EA (1) EA202092190A1 (es)
IL (1) IL277332B2 (es)
MX (1) MX2020009604A (es)
MY (1) MY205335A (es)
PE (1) PE20210158A1 (es)
PH (1) PH12020551468A1 (es)
SG (1) SG11202008971VA (es)
TW (1) TWI704917B (es)
WO (1) WO2019178492A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111936137B (zh) 2018-03-16 2023-09-08 安济药业公司 用于治疗严重便秘的组合物和方法
KR20220052459A (ko) 2020-10-21 2022-04-28 주식회사 엘지에너지솔루션 전극 탭 고정부를 포함하는 용접장치 및 이를 이용한 전극 탭 용접 방법

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3225997A (en) 1996-05-30 1998-01-05 Trustees Of Columbia University In The City Of New York, The Dna encoding acylcoenzyme a: cholesterol acyltransferase and uses thereof
US20030154504A1 (en) 1998-06-24 2003-08-14 Farese Robert V. Methods and compositions for modulating carbohydrate metabolism
US20030167483A1 (en) 1998-06-24 2003-09-04 Farese Robert V. Diacylglycerol O-acyltransferase
US6344548B1 (en) 1998-06-24 2002-02-05 The Regents Of The University Of California Diacylglycerol o-acyltransferase
WO1999067268A1 (en) 1998-06-24 1999-12-29 The Regents Of The University Of California Diacylglycerol o-acyltransferase
US6100077A (en) 1998-10-01 2000-08-08 The Trustees Of Columbia University In The City Of New York Isolation of a gene encoding diacylglycerol acyltransferase
US6635640B2 (en) 2000-06-30 2003-10-21 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
US6444427B1 (en) 2000-07-11 2002-09-03 The Regents Of The University Of California Polymorphisms in a diacylglycerol acyltransferase gene, and methods of use thereof
JP4164645B2 (ja) 2002-08-09 2008-10-15 株式会社大塚製薬工場 Ｄｇａｔ阻害剤
AU2003293006A1 (en) 2002-11-22 2004-06-18 Japan Tobacco Inc. Fused bicyclic nitrogen-containing heterocycles
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
AR044152A1 (es) 2003-05-09 2005-08-24 Bayer Corp Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
WO2005013907A2 (en) 2003-08-07 2005-02-17 Japan Tobacco Inc. Pyrrolo[1,2-b]pyridazine derivatives
GB0325192D0 (en) 2003-10-29 2003-12-03 Astrazeneca Ab Method of use
JP2005206492A (ja) 2004-01-21 2005-08-04 Sankyo Co Ltd スルホンアミド化合物
AU2005209115A1 (en) 2004-01-30 2005-08-11 Japan Tobacco Inc. Anorectic compounds
WO2006004200A1 (ja) 2004-07-02 2006-01-12 Sankyo Company, Limited ウレア誘導体
JP2006045209A (ja) 2004-07-02 2006-02-16 Sankyo Co Ltd ウレア誘導体
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
MX2007004217A (es) 2004-10-15 2007-06-11 Bayer Pharmaceuticals Corp Preparacion y uso de derivados de acido bifenil-4-il-carbonilamino para el tratamiento de obesidad.
WO2006064189A1 (en) 2004-12-14 2006-06-22 Astrazeneca Ab Oxadiazole derivatives as dgat inhibitors
JP2008536947A (ja) 2005-04-19 2008-09-11 バイエル・フアーマシユーチカルズ・コーポレーシヨン アリールアルキル酸誘導体およびそれらの使用
CN101595532B (zh) 2005-06-28 2013-07-31 E.I.内穆尔杜邦公司 缓冲组合物
AU2007245059B2 (en) * 2006-03-31 2011-07-28 Novartis Ag New compounds
GB0611506D0 (en) 2006-06-10 2006-07-19 Astrazeneca Ab Chemical compounds
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
WO2009112445A1 (en) * 2008-03-10 2009-09-17 Novartis Ag Method of increasing cellular phosphatidyl choline by dgat1 inhibition
WO2009126624A1 (en) 2008-04-11 2009-10-15 Bristol-Myers Squibb Company Triazolo compounds useful as dgat1 inhibitors
PH12012501859A1 (en) * 2010-03-30 2013-01-07 Novartis Ag Uses of dgat1 inhibitors
CA2794849A1 (en) * 2010-04-08 2011-10-13 Medicinova, Inc. Methods and compositions for the treatment of irritable bowel syndrome
AR083417A1 (es) * 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
WO2013130370A2 (en) * 2012-03-01 2013-09-06 Merck Sharp & Dohme Corp. Compounds as dgat-1 inhibitors
WO2013169648A1 (en) * 2012-05-07 2013-11-14 Novartis Ag Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug
HK1212222A1 (en) * 2012-08-29 2016-06-10 Salix Pharmaceuticals, Inc. Laxative compositions and methods for treating constipation and related gastrointestinal diseases and conditions
RU2016132340A (ru) * 2014-01-09 2018-02-14 Санофи Стабилизированные фармацевтические составы на основе инсулина аспарта
CN111936137B (zh) 2018-03-16 2023-09-08 安济药业公司 用于治疗严重便秘的组合物和方法

Also Published As

Publication number Publication date
CN111936137A (zh) 2020-11-13
PE20210158A1 (es) 2021-01-26
CN111936137B (zh) 2023-09-08
US20260000651A1 (en) 2026-01-01
KR102747096B1 (ko) 2024-12-26
EP3765012A4 (en) 2021-12-15
IL277332A (en) 2020-10-29
TW201944995A (zh) 2019-12-01
JP2021518431A (ja) 2021-08-02
MY205335A (en) 2024-10-16
TWI704917B (zh) 2020-09-21
SG11202008971VA (en) 2020-10-29
US12343334B2 (en) 2025-07-01
US20220193044A1 (en) 2022-06-23
AU2019234956A1 (en) 2020-10-01
CA3093970A1 (en) 2019-09-19
US11819495B2 (en) 2023-11-21
KR20200136428A (ko) 2020-12-07
IL277332B1 (en) 2024-09-01
US20190282549A1 (en) 2019-09-19
EA202092190A1 (ru) 2020-11-19
PH12020551468A1 (en) 2021-09-01
EP3765012A1 (en) 2021-01-20
IL277332B2 (en) 2025-01-01
US20240293376A1 (en) 2024-09-05
WO2019178492A1 (en) 2019-09-19
US11224590B2 (en) 2022-01-18
BR112020018790A2 (pt) 2020-10-13
AU2019234956B2 (en) 2025-01-30
JP7527984B2 (ja) 2024-08-05

Similar Documents

Publication Publication Date Title
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
MX2021005924A (es) Compuestos y metodos de uso de los mismos para el tratamiento del cancer.
WO2016106331A8 (en) Mutant idh1 inhibitors useful for treating cancer
EP4616913A3 (en) Gcn2 inhibitors and uses thereof
EP4635570A3 (en) Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
MX2021006575A (es) Composiciones y metodos para el tratamiento de trastornos del higado.
TN2019000110A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
EP4292588A3 (en) Administration of deuterated cftr potentiators
PH12016501338A1 (en) Indazole compounds as irak4 inhibitors
PH12016502005A1 (en) Compounds and compositions for inducing chondrogenesis
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
NZ752894A (en) Formulations for administration of eflornithine
RU2017116740A (ru) Комбинации для лечения рассеянного склероза
MX2016011105A (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos.
PH12017500029A1 (en) 4,5-dihydroisoxazole derivatives as nampt inhibitors
SA521421331B1 (ar) تركيبة صيدلانية تشتمل على عامل مضاد للصفيحات ومثبط إفراز حمض معدي
MX2022010748A (es) Metodos para tratar la glomeruloesclerosis segmentaria focal dependiente de apolipoproteina l1 (apol-1).
PH12019501642A1 (en) Novel compounds and their use in the treatment of schistosomiasis
MX2021002878A (es) Inhibidores de cd73 y usos farmaceuticos de los mismos.
PH12020551468A1 (en) Compositions and methods for treating severe constipation
EA202090445A1 (ru) ПРОТИВОГРИБКОВЫЕ СРЕДСТВА С ПОВЫШЕННОЙ АКТИВНОСТЬЮ ПРИ КИСЛОМ pH
MY209771A (en) Compounds for use in the treatment of fascioliasis
WO2020032885A3 (en) Capsule-in-capsule compositions of dabigatran etexilate
TH2001005221A (th) องค์ประกอบสำหรับการบำบัดอาการท้องผูกที่รุนแรง
TW201713630A (en) Substituted quinazoline compounds and methods of use thereof